Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04699903 · ClinicalTrials.gov registry record
Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood
A clinical trial, sponsored by Lumos Diagnostics.
- Completed
- Registry status
- 201
- Enrollment target
NCT04699903 is a clinical trial that has completed, run by Lumos Diagnostics. The registered enrollment target is 201 participants.
The verdict
NCT04699903 has completed, sponsored by Lumos Diagnostics.
- COMPLETED
- Registry status
- 201 participants
- Enrollment target
Study Summary
Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.
Interventions
- DIAGNOSTIC_TEST POC SARS-Cov-2 IgG Antibody test
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2021-01-05 |
| Est. Completion | 2021-04-09 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04699903
The ClinicalTrials.gov registry entry for NCT04699903 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Lumos Diagnostics, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which POC SARS-Cov-2 IgG Antibody test is the first listed.
NCT04699903 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04699903 about?
NCT04699903 is a clinical study titled "Clinical Evaluation of a Point-of-Care (POC), SARS-CoV-2 (COVID-19) IgG Antibody Test in Fingerstick Whole Blood". Prospective, multi-center, observational, blinded clinical trial to compare a new point of care (POC) SARS-CoV-2 IgG antibody test to a reference SARS-CoV-2 PCR test using fingerstick whole blood.
What is the current status of trial NCT04699903?
This trial is currently completed. The enrollment target is 201 participants. The study started on 2021-01-05. Estimated completion is 2021-04-09.
What interventions are being tested in trial NCT04699903?
The interventions under investigation include: POC SARS-Cov-2 IgG Antibody test (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT04699903?
This trial is sponsored by Lumos Diagnostics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.